The Global Nicotine Policy Index: Ranking Countries on Harm Reduction

If you were designing a nicotine policy from scratch, guided by the best available evidence, what would it look like? It would distinguish between products based on their risk profile, taxing and regulating combustible cigarettes most heavily while making non-combustible alternatives accessible and affordable. It would provide honest, accurate information about relative risks to enable informed consumer choice. It would restrict youth access to all nicotine products while preserving adult access to reduced-risk alternatives. And it would integrate harm reduction into the broader tobacco control framework, recognizing that the goal is to minimize death and disease, not to achieve nicotine abstinence. How do the world's actual nicotine policies measure up to this evidence-based ideal? This comparative assessment ranks 30 countries on five dimensions of harm-reduction-aligned policy: risk-proportionate regulation, honest communication, differential taxation, adult access, and youth protection.

The United Kingdom leads the global ranking by a substantial margin. The UK's policy framework explicitly recognizes the risk continuum, with Public Health England's 'at least 95% less harmful' estimate informing public communication. Vaping products are regulated as consumer goods with product standards, not as pharmaceuticals or tobacco products. The NHS actively promotes vaping as a cessation tool through the 'swap to stop' program, and hospitals have opened on-site vape shops. Taxation is differential, with vaping products taxed at far lower rates than cigarettes. The UK model is not perfect—youth vaping remains a concern, and the regulatory framework continues to evolve—but it's the closest any major country has come to implementing the harm-reduction framework that the evidence supports.

New Zealand ranks second, despite the repeal of its smokefree generation law. The country's vaping framework, which explicitly endorses vaping as a cessation tool while restricting youth access, remains among the world's most progressive. Vaping products are regulated as consumer goods, health authorities communicate honestly about relative risks, and the policy framework distinguishes clearly between combustible and non-combustible products. The Smokefree Aotearoa 2025 Action Plan, while stripped of its most ambitious provisions, retains a harm-reduction orientation that contrasts with the abstinence-oriented frameworks of peer countries.

Sweden ranks third, not because of its policies but because of its outcomes. Sweden's achievement—the lowest smoking rate and lowest tobacco-related mortality in Europe—was driven by consumer behavior (the shift from cigarettes to snus) rather than by proactive policy. But the outcome is the most important real-world evidence for harm reduction, and Sweden's regulatory framework, which taxes snus at lower rates than cigarettes and permits its sale as a consumer product, has enabled the transition. Sweden's experience is a model not of policy design but of policy non-interference with a consumer-driven harm-reduction transition.

Canada ranks in the middle tier, with a mixed framework that includes some harm-reduction elements (differential taxation, honest communication, access to vaping products through specialty retailers) alongside restrictive elements (flavor restrictions, nicotine concentration limits). The Canadian model represents an attempt to balance adult access with youth protection—a balance that's evident in the policy framework's internal tensions. Canada is a case study in the difficulty of implementing harm reduction when both the evidence and the politics pull in different directions.

Australia and the United States rank in the bottom tier, though for different reasons. Australia's prescription-only model for vaping effectively restricts access to the smokers who would benefit most from switching. The model prioritizes precaution over harm reduction, and the result is that most Australian smokers who want to switch to vaping cannot do so legally. The United States' fragmented regulatory landscape—PMTA denials, flavor bans at the state level, differential taxation that in some states treats vaping identically to smoking—produces outcomes that vary dramatically by jurisdiction but that, on average, are poorly aligned with the harm-reduction evidence. Both countries demonstrate how institutional commitments to the abstinence framework can override evidence of harm reduction's effectiveness.

The comparative assessment reveals patterns that are obscured by country-by-country analysis. First, the countries that have most fully embraced harm reduction are the ones with the fastest-declining smoking rates—the correlation between policy alignment and outcomes is consistent. Second, the primary barrier to harm reduction is not evidence—the evidence is robust and widely available—but institutional commitment to the abstinence framework, which is strongest in the countries (Australia, United States) where the tobacco control movement was built on opposition to the tobacco industry. Third, the countries that have adopted harm reduction have not experienced the youth vaping epidemics that critics predicted—the UK and New Zealand have lower youth vaping rates than the United States, despite more permissive policies. The evidence suggests that harm-reduction-oriented regulation, combined with strong youth-access enforcement, can achieve both adult smoking reduction and youth protection. The country ranking is not just a scorecard. It's a roadmap for where evidence-based nicotine policy is heading—and which countries are leading or lagging.